

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **July 17, 2017**

ACCURAY INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-33301

(Commission File Number)

20-8370041

(IRS Employer Identification No.)

**1310 Chesapeake Terrace
Sunnyvale, California 94089**

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: **(408) 716-4600**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On July 17, 2017, Accuray Incorporated (the "Company") issued a press release announcing certain preliminary estimated financial results for the Company for the quarter and year ended June 30, 2017. A copy of the Company's press release dated July 17, 2017, titled "Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results," is attached hereto as Exhibit 99.1.

The foregoing information (including the exhibit hereto) is being furnished under "Item 2.02 Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
--------------------	--------------------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCURAY INCORPORATED

Dated: July 17, 2017

By: _____
/s/ Kevin Waters
Kevin Waters
Senior Vice President & Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated July 17, 2017, titled "Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results."



Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results

Q4 Revenue Expected to be Approximately \$111.5-\$112 Million and Q4 Gross Orders Expected to be Approximately \$86 Million; Accuray Expects to Finish Fiscal Year with Approximately \$108 Million in Cash, Cash Equivalents & Investments

Preliminary Revenue and Product Order Results for Fourth Quarter and Fiscal Year 2017 Expected to be In Line with Guidance Provided in April

SUNNYVALE, Calif., July 17, 2017 – Accuray Incorporated (NASDAQ: ARAY) announced today preliminary revenue and product orders for the fourth quarter and full fiscal year ended June 30, 2017, that are in line with guidance provided in April. The company anticipates reporting its full financial results for the fourth quarter and fiscal year 2017 on August 22, 2017. The preliminary results reported have not been audited and are subject to change.

The company announced the following preliminary results for the fourth quarter and full fiscal year:

- Revenue for the fourth quarter is expected to be approximately \$111.5-\$112.0 million. For the full fiscal year, revenue is expected to be approximately \$382.8-\$383.3 million
- Gross product orders for the fourth quarter are expected to be approximately \$86 million; full fiscal year gross product orders are expected to be approximately \$298 million
- Ending backlog as of June 30th is expected to be approximately \$453 million, an increase of 12 percent over prior fiscal year
- Age-outs and cancellations during the fourth quarter are expected to be approximately \$19 million and \$4 million, respectively
- Cash, cash equivalents, investments and restricted cash are expected to be approximately \$108 million as of June 30, 2017, an increase of \$11.4 million from March 31, 2017, primarily due to working capital improvements offset by total debt reduction of \$10 million

“Our fourth quarter revenue growth was driven by improved performance in both our Europe and Asia Pacific regions and we finished the fiscal year with renewed momentum resulting from our increased focus on converting backlog to revenue,” said Joshua H. Levine, president and chief executive officer of Accuray. “We also had double digit gross order growth in the second half of the fiscal year, driven by the full commercial launch of our Radixact system and continued strong demand for our CyberKnife system. During the fourth quarter, we continued to improve the company’s balance sheet with a new \$52 million revolving loan agreement that reduces our annual interest costs by \$2 million versus our prior secured term loan and we reduced our total debt by \$10 million. As we look forward to fiscal year 2018, we strongly believe we have the people, processes and product roadmap in place for continued growth in orders, revenues and market share.”

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to: Accuray’s preliminary results for Q4 and fiscal year 2017, Accuray’s company trajectory, Accuray’s ability to achieve its strategic objectives with respect to its balance sheet and refinancing of its existing convertible debt, and Accuray’s leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K, filed on August 24, 2016, the company’s reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

###

Investor Contact:

Doug Sherk
Investor Relations, EVC Group
+1 (415) 652-9100
dsherk@evcgroup.com

Media Contact:

Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com

